久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

Thermo Fisher Openbiosystems      
Open Biosystems成立于2001年，是一家非常具有發(fā)展前景的美國生物公司。其2002年與IMAGE (Integrated Molecular Analysis of Genomes and their Expression）聯(lián)盟達(dá)成協(xié)議，面向全球銷售IMAGE聯(lián)盟所屬的基因資源。該公司可以提供的產(chǎn)品線主要有三個方面:
基因克隆：
可以提供IMAGE聯(lián)盟、MGC、Incyte、CGAP等組織的所有基因資源，數(shù)量達(dá)千萬個，包括人和小鼠的全長cDNA克隆、腫瘤基因組的EST、正常及腫瘤組織的全長cDNA克隆、大鼠和人的BAC克隆等。客戶可以單獨購買其中的個別克隆，也可以購買某一類型的克隆（BioTrack計劃，如MAPkinase信號途徑、糖酵解途徑、細(xì)胞凋亡、調(diào)節(jié)和代謝等生理途徑的cDNA克隆組合）或者整個文庫。可以這么說，Openbiosystems可以為您提供任何您所需要的基因克隆。

RNAi干擾文庫：

包括美國冷泉港（CSHL）實驗室Dr.Greg Hannon提供的基于改造的逆轉(zhuǎn)錄病毒載體的shRNA文庫（Expression Arrest shRNA Library）和有哈佛大學(xué)（Harvard) Steve Elledge提供的基于改造的假病毒載體的shRNA文庫（TRC）。構(gòu)建的shRNA文庫為大規(guī)模篩選基因功能提供了基礎(chǔ)。

抗體服務(wù)：

根據(jù)客戶的需求定制高質(zhì)量的抗體
 
We are part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings.

Open Biosystems was founded in 2001 by a team of researchers who believe deeply in the power of science to improve our lives, and yours, too. This conviction, coupled with our strong desire to help our customers succeed, motivates our employees and gives us our unrelenting focus on developing and delivering the best life sciences tools, support and services to our customers available in the industry today.

Our business model, based on a collaborative spirit and focused on the value of product delivery, is inspired by the success of the open source movement in software. Open source has, over the span of just a few years, radically empowered small organizations and individuals by giving them the tools only big companies could previously afford. We aim to speed the progress of research by letting people use our technology in a manner that’s substantially more flexible than that of other tools providers.

Open Biosystems offers products that span Genomics, RNAi and Antibodies. Building on the rapid sharing model that is at the core of the Human Genome Project, Open Biosystems collaborates with some of the most innovative life science investigators working today. We partner with them to bring to market new products—they have often pioneered the new resources in their own lab, and we prepare it for widespread use and then provide access to the research community.

Delivery of genetic content is our most recent technological breakthrough. Recently, we brought to market the Tranz-vector system, the safest human-based lentiviral delivery technology. Further supplementing our already strong line of RNA interference (RNAi) and complementary DNA (cDNA) products, this technology provides investigators with superior delivery capabilities for high-quality cellular screening. The combination or our unique Tranz-vector system and whole genome RNAi & cDNA content enables our customers to perform drug target validation on a large scale.

With our genomics resources, Open Biosystems provides the content investigators utilize to unlock the functions of human genes and their relationships to normal & disease development. We offer the most complete gene library in the industry. This novel library consists of several full length cDNA and open reading frame collections. Most prominently among these is the Mammalian Gene Collection (MGC), the industry’s gold standard gene catalog.

The discovery of RNA interference has revolutionized the way investigators approach the studies of gene expression, regulation and interactions, particularly as it relates to drug development. Our collaboration with Drs. Greg Hannon (CSHL) and Steve Elledge (Harvard) has led the way in the evolution of the short hairpin RNA (shRNA) technologies to provide the life science community with whole genome resources for human, mouse and rat with a multitude of technology and delivery advantages.